Literature DB >> 11140870

The role of sentinel lymph nodes in malignant melanoma.

S P Leong1.   

Abstract

Selective sentinel lymph node dissection should be considered a standard approach in the treatment of primary malignant melanoma. With the combination of blue dye and radioisotope mapping, the sentinel lymph nodes (SLNs) can be harvested with pinpoint accuracy. This article compares blue dye and radioisotope mapping techniques. Based on the clinical outcome data of selective sentinel lymph node dissection, micrometastasis to the SLNs carries a poor prognosis for patients with primary invasive melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140870     DOI: 10.1016/s0039-6109(05)70258-9

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Is there a role for lymphoscintigraphy and sentinel node biopsy in the management of the regional lymphatics in mucosal squamous cell carcinoma of the head and neck?

Authors:  Nicholas Hyde; Elizabeth Prvulovich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-27       Impact factor: 9.236

Review 2.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

3.  Current status of sentinel lymph node biopsy in solid malignancies.

Authors:  Amit Goyal; Robert E Mansel
Journal:  World J Surg Oncol       Date:  2004-04-24       Impact factor: 2.754

Review 4.  Sentinel lymph node biopsy in esophageal cancer: an essential step towards individualized care.

Authors:  George L Balalis; Sarah K Thompson
Journal:  Ann Surg Innov Res       Date:  2014-05-05

5.  Report on fluorescence lifetime imaging using multiphoton laser scanning microscopy targeting sentinel lymph node diagnostics.

Authors:  Jeemol James; Despoina Kantere; Jonas Enger; Jan Siarov; Ann Marie Wennberg; Marica B Ericson
Journal:  J Biomed Opt       Date:  2020-03       Impact factor: 3.170

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.